NO20072325L - Kombinasjonsterapi omfattende telmisartan og hydroklortiazid - Google Patents

Kombinasjonsterapi omfattende telmisartan og hydroklortiazid

Info

Publication number
NO20072325L
NO20072325L NO20072325A NO20072325A NO20072325L NO 20072325 L NO20072325 L NO 20072325L NO 20072325 A NO20072325 A NO 20072325A NO 20072325 A NO20072325 A NO 20072325A NO 20072325 L NO20072325 L NO 20072325L
Authority
NO
Norway
Prior art keywords
hydrochlorothiazide
telmisartan
combination therapy
therapy including
approx
Prior art date
Application number
NO20072325A
Other languages
English (en)
Norwegian (no)
Inventor
Axel Riedel
Helmut E Schumacher
Peter Boehm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072325(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20072325L publication Critical patent/NO20072325L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
NO20072325A 2004-12-17 2007-05-04 Kombinasjonsterapi omfattende telmisartan og hydroklortiazid NO20072325L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17
PCT/EP2005/013224 WO2006063737A1 (fr) 2004-12-17 2005-12-09 Therapie combinatoire impliquant le telmisartan et l'hydrochlorothiazide

Publications (1)

Publication Number Publication Date
NO20072325L true NO20072325L (no) 2007-07-06

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072325A NO20072325L (no) 2004-12-17 2007-05-04 Kombinasjonsterapi omfattende telmisartan og hydroklortiazid

Country Status (15)

Country Link
EP (1) EP1827424A1 (fr)
JP (1) JP2008524136A (fr)
KR (1) KR20070097511A (fr)
CN (1) CN101080225A (fr)
AR (1) AR052052A1 (fr)
AU (1) AU2005315855A1 (fr)
BR (1) BRPI0519656A2 (fr)
CA (1) CA2589493A1 (fr)
EA (1) EA200701159A1 (fr)
IL (1) IL183944A0 (fr)
NO (1) NO20072325L (fr)
PE (1) PE20060768A1 (fr)
TW (1) TW200637546A (fr)
UY (1) UY29274A1 (fr)
WO (1) WO2006063737A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (fr) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Composition pharmaceutique
SI2180882T1 (sl) † 2007-10-19 2013-05-31 Otsuka Pharmaceutical Co., Ltd. Trdni matriksni farmacevtski pripravek
EP2203158A4 (fr) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr Formulations pharmaceutiques comprenant du telmisartan et de l'hydrochlorotiazide
CA2715350C (fr) 2008-03-19 2017-02-14 Ratiopharm Gmbh Composition pharmaceutique solide incluant un antagoniste non peptidique du recepteur de l'angiotensine ii et un diuretique
PE20110551A1 (es) * 2008-07-31 2011-09-02 Takeda Pharmaceutical Composicion farmaceutica solida que contiene un derivado de bencimidazol y un diuretico
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
WO2010146187A2 (fr) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Procédé pour la préparation de telmisartan
EP2448576A2 (fr) * 2009-07-02 2012-05-09 Mahmut Bilgic Composition pharmaceutique augmentant la solubilité
WO2011002425A2 (fr) * 2009-07-02 2011-01-06 Bilgig Mahmut Composition pharmaceutique présentant une solubilité et une stabilité accrues
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (fr) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Comprimé pharmaceutique multicouche comprenant du telmisartan et un diurétique
WO2014119767A1 (fr) * 2013-01-31 2014-08-07 沢井製薬株式会社 Comprimé multicouche contenant du telmisartan et de l'hydrochlorothiazide
JP6422868B2 (ja) * 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
PT1854454E (pt) * 2002-01-16 2014-01-09 Boehringer Ingelheim Pharma Método para a preparação de telmisartan amorfo

Also Published As

Publication number Publication date
TW200637546A (en) 2006-11-01
AU2005315855A1 (en) 2006-06-22
PE20060768A1 (es) 2006-09-29
WO2006063737A1 (fr) 2006-06-22
EP1827424A1 (fr) 2007-09-05
CN101080225A (zh) 2007-11-28
IL183944A0 (en) 2007-10-31
AR052052A1 (es) 2007-02-28
EA200701159A1 (ru) 2007-12-28
KR20070097511A (ko) 2007-10-04
CA2589493A1 (fr) 2006-06-22
BRPI0519656A2 (pt) 2009-03-03
UY29274A1 (es) 2006-07-31
JP2008524136A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
NO20072325L (no) Kombinasjonsterapi omfattende telmisartan og hydroklortiazid
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
JP6151123B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
RU2010135831A (ru) Способы, лекарственные формы и наборы для введения зипрасидона без пищи
WO2004017896A3 (fr) Traitement combine faisant intervenir un double agoniste de ppar alpha/gamma et un recepteur de type i d'angiotensine ii
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
MXPA05008461A (es) Equipo para aplicar revestimiento de farmaco a un dispositivo medico en un cuarto del cirujano.
AR034517A1 (es) Formulacion farmaceutica
WO2009045309A3 (fr) Utilisation d'antagonistes des récepteurs v2 en combinaison avec des agonistes vasopressinergiques
WO2010045417A3 (fr) Polytherapies pour le traitement de l'obesite
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
WO2007098387A3 (fr) Traitement antihypertenseur
JP7109092B2 (ja) リドカインおよびジクロフェナクを含む神経障害性疼痛の治療用の医薬用貼付剤
WO2004096118A3 (fr) Composition permettant d'ameliorer la cognition et la memoire
CL2007003484A1 (es) Composicion farmaceutica que comprende valsartan y un tensoactivo, un componente lipofilico y un componente hidrofilico; procedimiento de preparacion; y uso en el tratamiento de la insuficiencia cardiaca, angina, infarto de miocardio, arterioescleros
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
SE9902597D0 (sv) New use
WO2004037199A3 (fr) Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation
JP7109093B2 (ja) リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
PT1408977E (pt) Terapia de combinacao para o tratamento de falha cardiaca
ECSP11010999A (es) Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application